Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer

Comprehensive characterization of the genomic landscape of epidermal growth factor receptor (EGFR)-mutated lung cancers have identified patterns of secondary mutations beyond the primary oncogenic EGFR mutation. These include concurrent pathogenic alterations affecting p53 (60–65%), RTKs (5–10%), PI...

Descripción completa

Detalles Bibliográficos
Autores principales: Gini, Beatrice, Thomas, Nicholas, Blakely, Collin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Mechanisms of Resistance to EGFR-targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330397/
https://www.ncbi.nlm.nih.gov/pubmed/32642201
http://dx.doi.org/10.21037/jtd.2020.03.78

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330397/
https://www.ncbi.nlm.nih.gov/pubmed/32642201
http://dx.doi.org/10.21037/jtd.2020.03.78

Ejemplares similares